BioEclipse Therapeutics
BioEclipse Therapeutics is a clinical-stage oncology company dedicated to developing next-generation immuno-oncology therapeutics. They focus on harnessing a refined understanding of the human immune system to create multi-mechanistic, targeted treatments that aim to eradicate cancer cells and prevent relapse through durable immune responses. Their proprietary platform technology includes low-cost allogeneic and autologous therapies designed to treat resistant and recurrent solid tumors, with ongoing clinical trials and a mission to transform cancer therapies from treatment to cures.
Industries
Nr. of Employees
small (1-50)
BioEclipse Therapeutics
319 N. Bernardo Avenue, Mountain View, CA 94043
Products
CRX100 (autologous engineered cell therapy)
Autologous engineered immune cell therapeutic delivered intravenously and evaluated in Phase 1b for refractory solid tumors; studied in combination with oncolytic virus in early clinical cohorts.
CRX200 (allogeneic off-the-shelf cell therapy)
Allogeneic, off-the-shelf engineered cell therapeutic described as IND-ready and designed to reduce patient burden by avoiding apheresis and lowering required infusion frequency and dose.
CRX100 (autologous engineered cell therapy)
Autologous engineered immune cell therapeutic delivered intravenously and evaluated in Phase 1b for refractory solid tumors; studied in combination with oncolytic virus in early clinical cohorts.
CRX200 (allogeneic off-the-shelf cell therapy)
Allogeneic, off-the-shelf engineered cell therapeutic described as IND-ready and designed to reduce patient burden by avoiding apheresis and lowering required infusion frequency and dose.
Services
Design and execution of Phase 1, open-label, dose-escalation trials for engineered cell therapeutics, including site enrollment and early safety/efficacy assessment.
Preclinical program design and execution demonstrating potency of engineered cell therapeutics across multiple tumor types.
Preparation of IND-enabling documentation and navigation of regulatory milestones to achieve IND-ready status for cell therapy candidates.
Operational capabilities to meet manufacturing and cold-chain shipping requirements for cellular products, supporting scalable distribution and reduced per-dose burdens.
Design and execution of Phase 1, open-label, dose-escalation trials for engineered cell therapeutics, including site enrollment and early safety/efficacy assessment.
Preclinical program design and execution demonstrating potency of engineered cell therapeutics across multiple tumor types.
Preparation of IND-enabling documentation and navigation of regulatory milestones to achieve IND-ready status for cell therapy candidates.
Operational capabilities to meet manufacturing and cold-chain shipping requirements for cellular products, supporting scalable distribution and reduced per-dose burdens.
Expertise Areas
- Clinical trial management (Phase 1 dose-escalation)
- Adoptive cell therapy development
- Allogeneic cell therapy platforms
- Autologous cell therapy development
Key Technologies
- Adoptive cell therapy (NK-like T cells)
- Allogeneic cell therapy platforms
- Autologous engineered cell therapeutics
- Oncolytic vaccinia virus therapy
News & Updates
BioEclipse Therapeutics announced it has been awarded a $7,999,689 grant by CIRM to support its ongoing clinical study: A Phase 1, open-label, dose-escalation study of CRX100 in patients with advanced solid tumors.
Combination treatment with the novel adoptive Natural Killer-Like T (NK-T) cell therapy CRX100 and a tumor-specific oncolytic vaccinia virus generated responses and was well tolerated in a small cohort of patients with recurrent, platinum-resistant ovarian cancer.
BioEclipse Therapeutics announced the initiation of patient enrollment at the HonorHealth Research Institute in Scottsdale, Ariz., for a Phase 1 dose-escalation trial to treat refractory solid tumors, marking the first-in-human study of CRX100.
BioEclipse Therapeutics CEO, Dr. Pamela Contag, is named in Top 50 Women Leaders of San Jose for 2024 by 'Women We Admire' magazine.
BioEclipse Therapeutics announced it has been awarded a $7,999,689 grant by CIRM to support its ongoing clinical study: A Phase 1, open-label, dose-escalation study of CRX100 in patients with advanced solid tumors.
Combination treatment with the novel adoptive Natural Killer-Like T (NK-T) cell therapy CRX100 and a tumor-specific oncolytic vaccinia virus generated responses and was well tolerated in a small cohort of patients with recurrent, platinum-resistant ovarian cancer.
BioEclipse Therapeutics announced the initiation of patient enrollment at the HonorHealth Research Institute in Scottsdale, Ariz., for a Phase 1 dose-escalation trial to treat refractory solid tumors, marking the first-in-human study of CRX100.
BioEclipse Therapeutics CEO, Dr. Pamela Contag, is named in Top 50 Women Leaders of San Jose for 2024 by 'Women We Admire' magazine.